Whalesbook
Medanta's Noida Unit Fuels Analyst Optimism
Global Health (Medanta) is drawing renewed analyst attention. Despite recent stock price drops linked to the Noida facility launch and broader market factors, JM Financial has reaffirmed its 'Buy' rating. Analysts believe these issues are temporary, highlighting Medanta's established advanced medical services and ambitious plans to boost its bed capacity, which are expected to drive future profit and earnings growth.
Noida Facility's Path to Profitability
According to JM Financial, the Noida facility's performance in Q3FY26, which saw revenues of ₹343 crore and an EBITDA loss of ₹320 crore, marks the peak of its initial investment phase. Costs for hiring and setup are mostly absorbed, and the unit is steadily increasing operations by adding beds and operating rooms. New specialty services and expected approvals for radiation oncology are set to boost revenue and improve the mix of services. Importantly, achieving NABH accreditation is speeding up patient enrollments, with revenue impacts expected from February 2026. While Q4FY26 losses are forecast at ₹20-25 crore, analysts see clear signs of future profit from operations and potential demand from the nearby Jewar airport, pointing to a positive outlook for this key project. Key patient enrollments are expected to significantly boost revenue from February 2026, with a steady quarterly buildup projected toward ₹60 crore.
Established Network and Expansion Goals
Medanta's existing hospital network is also performing well, showing mid-teen year-on-year growth in the first nine months of FY26 and stable EBITDA margins. The company has limited exposure to geopolitical risks in the Middle East, which reduces concerns about disruptions to international patient numbers, while domestic demand is expected to offset any temporary slowdowns. Management plans to add 496 beds through expansions at current facilities and aims to build four new hospitals, targeting a total of 6,375 beds by FY29. This careful investment strategy aims to improve overall network profitability and build on its strong clinical reputation and doctor-led brand. This support allows for higher average revenue per patient (ARPPs) compared to rivals like Max Healthcare Institute. Medanta’s average revenue per occupied bed (ARPOB) was ₹67,361 in Q3 FY26, reflecting its premium market standing.
Valuation Concerns and Competitive Landscape
Despite the positive outlook, Medanta's stock trades at 21 times its projected FY27 earnings before interest, taxes, depreciation, and amortization (EBITDA), a 25% discount to its usual valuation. This lower price might stem from market worries about the Noida unit's initial losses and general geopolitical risks, which JM Financial views as temporary. While Medanta is expanding rapidly, it faces strong competition from established companies like Apollo Hospitals and Fortis Healthcare, who also have major expansion plans and significant market share. Some analysts are hesitant about the stock's price-to-earnings (P/E) multiple, which is higher than the Indian market average and some competitors, questioning if the valuation is sustainable if earnings growth slows. A point of concern is the drop in operating margins in Q3 FY26 to 19.38% from 25.20% a year earlier, partly due to higher employee costs and depreciation from new facilities. Although Medanta has a net cash position and no promoter shares are pledged, its revenue grew about 18-19% year-on-year in Q3 FY26, while net profit (PAT) fell sharply by 33.5%. This drop was due to one-off costs, including those related to new labor laws and the Noida facility, raising questions about cost control during expansion.
Analyst Confidence and Growth Forecasts
JM Financial is maintaining its 'Buy' recommendation with a price target of ₹1,382, suggesting a potential 42.47% increase from the current stock price. This target is based on 25 times projected FY28 EBITDA, showing confidence in the company's predictable earnings, potential for margin improvement, and a better valuation environment. The firm forecasts average annual growth rates (CAGRs) of 14% for revenue and 26% for EBITDA between FY26 and FY28. The overall Indian healthcare market is expected to grow by up to 12% annually over the next three to five years, fueled by government support, increasing health issues, and growing medical tourism. Medanta's strategic expansion and focus on advanced medical treatments place it well within this growth trend. Most analysts recommend 'Outperform' for the stock, with average target prices around ₹1,293.27.